Lung Cancer Clinical Trial

Inspiratory Muscle Training and Behavioral Support to Alleviate Dyspnea and Promote Walking in Lung Cancer Survivors: A Pilot Study

Summary

This is a pilot randomized study to investigate the feasibility, acceptability, safety, and effects of a novel tele-rehabilitation intervention for stage I-IIIA lung cancer survivors following curative intent therapy.

The specific aims and hypotheses are:

Specific Aim 1: Conduct a pilot, phase IIb, parallel randomized (1:1) study to investigate the feasibility, acceptability, and safety of inspiratory muscle training and behavioral support to promote walking in tele-rehabilitation with stage I-IIIA lung cancer survivors following curative intent therapy (N=40).

Hypothesis 1a: ≥ 20% eligible patients will enroll; ≥75% of participants will achieve ≥75% adherence to the tele-rehabilitation program.

Hypothesis 1b: ≥75% of participants will perceive tele-rehabilitation as acceptable (Telemedicine Satisfaction and Usefulness Questionnaire ≥4). There will be 0 intervention adverse events.

Specific Aim 2: Explore the effects of the tele-rehabilitation program (N=40).

Hypothesis 2: At 12 weeks, participants in the tele-rehabilitation (experimental) arm, compared to education only (control) arm, will have a trend of greater improvements in outcomes, including:

accelerometry-measured physical activity (primary outcome); and
functional capacity, self-reported physical activity, control of dyspnea and anxiety symptoms, sleep quality, and quality of life (secondary outcomes).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

history of stage I-IIIA lung cancer;
completed curative intent therapy (i.e., lung cancer resection surgery, definitive radiation, or concurrent chemoradiation) within 1-6 months;
access to a mobile phone or personal computer with internet access;
willingness to wear activity trackers

Exclusion Criteria:

dementia (or cognitive impairment identified by chart review) resulting in inability to follow directions or provide written informed consent;
acute myocardial infarction, ventricular tachycardia, ventricular fibrillation, acute cerebrovascular event, or acute asthma exacerbation in past 2 months;
spontaneous pneumothorax in past 12 months;
Parkinson's disease;
multiple sclerosis;
amyotrophic lateral sclerosis;
additional movement/gait disorders that may be identified by chart review

Study is for people with:

Lung Cancer

Estimated Enrollment:

31

Study ID:

NCT05059132

Recruitment Status:

Completed

Sponsor:

Kaiser Permanente

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Kaiser Permanente Colorado
Aurora Colorado, 80014, United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Estimated Enrollment:

31

Study ID:

NCT05059132

Recruitment Status:

Completed

Sponsor:


Kaiser Permanente

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.